- Sagimet Biosciences, a San Mateo, Calif.-based clinical-stage biotechnology company, raised $80m in crossover financing
- The round led by an undisclosed public equity healthcare investment fund with participation from existing investors along with new investors
- The company intends to use the funds to advance its lead program, TVB-2640 for NASH, to explore additional indications, to file an IND on a second FASN inhibitor, TVB-3567
- Sagimet isa clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers
- Sagimet advancing TVB-2640, an oral, first-in-class fatty acid synthase (FASN) inhibitor, including a planned Phase 2b trial evaluating the impact on histological endpoints
- The company also provided an update regarding changes and additions to its board of directors
